Nanotechnology-Based Pharmacological Treatment for Brain Tumors

One of the most aggressive forms of cancer, brain tumors, especially glioblastoma multiforme (GBM), have a short survival period and a high death rate. It is estimated that 94,390 new cases of primary brain and other central nervous system (CNS) tumors would occur in the United States alone in 2023. The blood-brain barrier's (BBB) protective role and the aggressive nature of GBM provide significant therapeutic challenges. The inability to accurately target tumor cells without harming nearby healthy tissue, poor drug penetration through the blood-brain barrier, and resistance to conventional therapies are some of the drawbacks of current treatments like radiation, chemotherapy, and surgery. A potential solution to these issues is drug delivery systems based on nanotechnology. Nanoparticles, such as carbon-based nanomaterials, liposomes, and polymeric nanoparticles, enhance drug solubility, target certain cells, and enable controlled release. Because of this, therapeutic medications can more easily cross the blood-brain barrier and build up at the tumor site, reducing systemic toxicity. With an emphasis on the advantages of various nanoparticle systems, such as liposomes, polymeric nanoparticles, stimulus-responsive nanoparticles, and carbon nanotubes, this study explores the application of nanotechnology in the treatment of brain tumors. The study examines the shortcomings of existing treatments for brain cancer and how nanodelivery systems can address these issues, ultimately providing a response to the following research question: How can drug delivery systems based on nanotechnology enhance the effectiveness of treatments for brain tumors?.